Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Clene

Benzinga's Top Ratings Upgrades, Downgrades For October 4, 2022

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Why Clene Shares Are Rising

Why Clene Shares Are Rising

Clene Inc. (NASDAQ: CLNN) shares are trading higher by 10.81% at $2.46 after the company received a $3 million loan from the Maryland Board of Public Works to support production for its lead drug candidate CNM-Au8.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap: Clene Q1 Earnings

Clene (NASDAQ:CLNN) reported its Q1 earnings results on Monday, May 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022

Clene Nanomedicine Presents Updated Data From Mid-Stage Amyotrophic Lateral Sclerosis Trials

Clene Inc (NASDAQ: CLNN) has announced multiple presentations of

Organisations

Paramount Global

B of A Securities

Gilead Sciences

Evercore ISI Group

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

Multiple Sclerosis

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

128,302 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play